ID   MMAc-SF
AC   CVCL_1420
SY   MMAC-SF; MMAc.SF; MMACSF; MMAc-Serum Free
DR   CLO; CLO_0050088
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03481114
DR   Cell_Model_Passport; SIDM01242
DR   ChEMBL-Cells; CHEMBL3308270
DR   ChEMBL-Targets; CHEMBL2366196
DR   Cosmic; 925339
DR   Cosmic-CLP; 925339
DR   DepMap; ACH-002162
DR   EGA; EGAS00001000978
DR   GDSC; 925339
DR   GEO; GSM1670119
DR   IARC_TP53; 27564
DR   LINCS_HMS; 50999
DR   LINCS_LDP; LCL-1277
DR   PharmacoDB; MMACSF_945_2019
DR   RCB; RCB1200
DR   Wikidata; Q54906202
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Group: Serum/protein free medium cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.62%; Native American=0.05%; East Asian, North=77.21%; East Asian, South=20.11%; South Asian=1.76%; European, North=0%; European, South=0.25% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,12
ST   D16S539: 9,12
ST   D5S818: 12
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_5951 ! MMAc
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 29
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//